GLP-1 Agonists Linked to Lower Asthma Exacerbation Risk in Non-Diabetic Patients
The risk of asthma exacerbations appears to be reduced for individuals without diabetes who are taking GLP-1 receptor agonists, even across varying levels of body mass index (BMI), according to research presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. This finding suggests a potential new avenue for therapeutic intervention in obesity-associated asthma, extending beyond the established benefits of these medications for weight management and glucose control.
GLP-1s and Respiratory Health: Emerging Connections
Researchers, led by Ruchi Patel, MD, a resident physician at Rutgers New Jersey Medical School, conducted a real-world retrospective cohort study using data from the TriNetX global collaborative network. The study focused on patients without diabetes who had been diagnosed with asthma and categorized them into three weight classes: overweight (BMI 25 kg/m2-29.99 kg/m2), obese (BMI 30 kg/m2-40 kg/m2), and morbidly obese (BMI at least 40 kg/m2). The goal was to assess the impact of GLP-1 receptor agonist treatment on the risk of asthma exacerbations. The initial signal prompting this investigation came from observing potential improvements in asthma outcomes among patients prescribed GLP-1 medications, prompting a deeper appear beyond the diabetic population.
To account for potential biases, the researchers employed propensity scores to match patients receiving GLP-1 receptor agonists with a control group who were not. This resulted in a study population of 710 patients with overweight, 1,515 with obesity, and 1,249 with morbid obesity.
Consistent Risk Reduction Across BMI Categories
The results demonstrated a significant reduction in asthma exacerbation risk among overweight patients taking GLP-1 receptor agonists, with a relative risk (RR) of 0.748, representing a 14.6% decrease. This pattern persisted in both obese and morbidly obese patients. Obese patients experienced a 12.2% reduction in exacerbation risk (RR = 0.79), while those with morbid obesity saw a risk difference of 13.3% (RR = 0.78). “What was striking was how consistent the reduction in exacerbations was across all BMI categories,” Patel told Healio. “The magnitude of the absolute risk reduction was too larger than expected.”
GLP-1 receptor agonists are a class of medications originally developed to treat type 2 diabetes. They perform by mimicking the effects of glucagon-like peptide-1 (GLP-1), a natural hormone that helps regulate blood sugar levels. These medications have gained increasing attention for their effectiveness in promoting weight loss, leading to their off-label utilize for obesity management. Previous research has indicated potential benefits of GLP-1 receptor agonists in improving asthma control in patients with both asthma, and obesity.
Understanding the Potential Mechanisms
While the precise mechanisms underlying the observed benefits remain unclear, several hypotheses are being explored. One possibility is that GLP-1 receptor agonists exert anti-inflammatory effects, which could help reduce airway inflammation in asthma. Another potential mechanism involves the impact of weight loss on lung function and airway responsiveness. Obesity is known to be associated with increased airway inflammation and reduced lung capacity, and weight loss can improve these parameters. A related study found reduced asthma exacerbation risk linked to GLP-1 receptor agonist use in youth with obesity.
Study Limitations and Future Directions
It’s important to note that this study was retrospective in nature, which means it cannot establish a causal relationship between GLP-1 receptor agonist use and reduced asthma exacerbations. Retrospective studies are susceptible to confounding factors and selection bias. For example, patients prescribed GLP-1 receptor agonists may have been more likely to receive other asthma treatments or to engage in healthier lifestyle behaviors, which could have contributed to the observed benefits. The study relied on data from electronic health records, which may not always be complete or accurate.
Patel and colleagues emphasize the need for prospective, randomized controlled trials to confirm these findings and to further elucidate the mechanisms involved. Future studies should directly measure lung function, inflammation, and weight change to provide a more comprehensive understanding of how GLP-1 medications impact asthma outcomes. These trials should also consider the potential for differential effects based on asthma severity, medication adherence, and other patient characteristics.
Implications for Clinical Practice and Public Health
The findings from this study suggest that GLP-1 receptor agonists may offer a novel therapeutic approach for managing asthma, particularly in patients with obesity. However, It’s crucial to emphasize that these medications should not be considered a substitute for standard asthma treatments, such as inhaled corticosteroids and bronchodilators. The decision to use GLP-1 receptor agonists in asthma management should be made on an individual basis, taking into account the patient’s overall health status, weight, and other relevant factors.
The Supreme Court of Georgia recently issued an email scam alert, warning of fraudulent emails impersonating court staff. While unrelated to GLP-1s and asthma, this serves as a reminder to be vigilant about potential scams and to verify the authenticity of any unsolicited communications. Similarly, the USCIS has announced updates regarding H-1B visa registration, opening on March 4, 2026, and premium processing fees, which will be increased to reflect inflation. More information can be found on the USCIS website.
As research continues to unravel the complex interplay between obesity, inflammation, and respiratory health, GLP-1 receptor agonists may emerge as a valuable tool in the comprehensive management of asthma. However, further investigation is needed to fully understand their potential benefits and risks, and to determine the optimal strategies for their use in clinical practice.
Ruchi Patel, MD, can be reached at [email protected].
Be aware of potential scams targeting individuals through text or email, posing as someone in authority requesting gift cards. The Department of Consumer and Community Affairs of Hawaii has issued a warning about this type of fraud.